News
Watch
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Richard L. Kravitz, MD, MSPH

Articles by Richard L. Kravitz, MD, MSPH

Physician Communication About the Cost and Acquisition of Newly Prescribed Medications

ByDerjung M. Tarn, MD, PhD,Debora A. Paterniti, PhD,John Heritage, PhD,Ron D. Hays, PhD,Richard L. Kravitz, MD, MSPH,Neil S. Wenger, MD, MPH

November 1st 2006

Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?

ByWilliam H. Shrank, MD, MSHS,George J. Joseph, MS,Niteesh K. Choudhry, MD, PhD,Henry N. Young, PhD,Susan L. Ettner, PhD,Peter Glassman, MBBS, MSc,Steven M. Asch, MD, MPH,Richard L. Kravitz, MD, MSPH

September 1st 2006

Attitudes and Behavioral Intentions Regarding Managed Care: A Comparison of Academic and Community Physicians

ByGarrett E. Foulke, MD,Robert A. Bell, PhD,Allan D. Siefkin, MD,Richard L. Kravitz, MD, MSPH

April 1st 1998

Physicians' Attitudes Toward Managed Care: Assessment and Potential Effects on Practice Behaviors

ByRobert A. Bell, PhD,Richard L. Kravitz, MD, MSPH,Allan D. Siefkin, MD,Garrett E. Foulke, MD

September 1st 1997

Managed Care Cost Containment and the Law of Unintended Consequences

ByRichard L. Kravitz, MD, MSPH,Patrick S. Romano, MD, MPH

March 1st 1996

Latest Updated Articles

Managed Care Cost Containment and the Law of Unintended Consequences
March 1st 1996
Physicians' Attitudes Toward Managed Care: Assessment and Potential Effects on Practice Behaviors
September 1st 1997
Attitudes and Behavioral Intentions Regarding Managed Care: A Comparison of Academic and Community Physicians
April 1st 1998
Physicians' Perceptions of Relevant Prescription Drug Costs: Do Costs to the Individual Patient or to the Population Matter Most?
September 1st 2006
Physician Communication About the Cost and Acquisition of Newly Prescribed Medications
November 1st 2006

Trending on AJMC

FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer

FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia

Bumetanide Nasal Spray Targets Heart Failure Edema Before IV

Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD

5 Things to Know if Retatrutide Is Classified as a Biologic